Management of primary plantar hyperhidrosis with botulinum toxin type A: A retrospective case series of 129 patients.
botulinum toxin
hyperhidrosis
plantar hyperhidrosis
quality of life
treatment
Journal
The Australasian journal of dermatology
ISSN: 1440-0960
Titre abrégé: Australas J Dermatol
Pays: Australia
ID NLM: 0135232
Informations de publication
Date de publication:
14 Nov 2023
14 Nov 2023
Historique:
revised:
29
09
2023
received:
23
04
2023
accepted:
31
10
2023
medline:
15
11
2023
pubmed:
15
11
2023
entrez:
15
11
2023
Statut:
aheadofprint
Résumé
To date, scientific data on the efficacy of botulinum toxin type A (BoNT-A) for primary plantar hyperhidrosis (PPH) are mainly derived from case reports and small case series. Herein, we sought to assess the efficacy and safety of BoNT-A for PPH on a large series of patients. Medical records of patients who were referred to the outpatient department for hyperhidrosis of a tertiary care hospital and received BoNT-A for PPH from March 2003 until December 2022 were reviewed. A total of 129 patients [12 males, 117 females; median age 32 years (range, 16-72)] were included in the study, after excluding 24 patients with insufficient documented follow-up data. Most patients [115 (89.1%)] received onabotulinumtoxin-A, nine (7.0%) abobotulinumtoxin-A and five (3.9%) both in subsequent sessions. The mean number of sessions was 2.02 [standard deviation (SD), 2.29] and the mean duration of response 6.16 months (SD, 4.01). The percentage of response, as evaluated by Minor's test, was 71.67%, 63.44%, 47.78% and 34.13% after 1, 3, 6 and 9 months, respectively. Most patients were satisfied (21.7%) or very satisfied (58.9%) with the treatment. No serious side effects were reported. The results of this retrospective study suggest that BoNT-A is an effective and safe treatment option for PPH.
Sections du résumé
BACKGROUND/OBJECTIVES
OBJECTIVE
To date, scientific data on the efficacy of botulinum toxin type A (BoNT-A) for primary plantar hyperhidrosis (PPH) are mainly derived from case reports and small case series. Herein, we sought to assess the efficacy and safety of BoNT-A for PPH on a large series of patients.
METHODS
METHODS
Medical records of patients who were referred to the outpatient department for hyperhidrosis of a tertiary care hospital and received BoNT-A for PPH from March 2003 until December 2022 were reviewed.
RESULTS
RESULTS
A total of 129 patients [12 males, 117 females; median age 32 years (range, 16-72)] were included in the study, after excluding 24 patients with insufficient documented follow-up data. Most patients [115 (89.1%)] received onabotulinumtoxin-A, nine (7.0%) abobotulinumtoxin-A and five (3.9%) both in subsequent sessions. The mean number of sessions was 2.02 [standard deviation (SD), 2.29] and the mean duration of response 6.16 months (SD, 4.01). The percentage of response, as evaluated by Minor's test, was 71.67%, 63.44%, 47.78% and 34.13% after 1, 3, 6 and 9 months, respectively. Most patients were satisfied (21.7%) or very satisfied (58.9%) with the treatment. No serious side effects were reported.
CONCLUSIONS
CONCLUSIONS
The results of this retrospective study suggest that BoNT-A is an effective and safe treatment option for PPH.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023 Australasian College of Dermatologists.
Références
Doolittle J, Walker P, Mills T, Thurston J. Hyperhidrosis: an update on prevalence and severity in the United States. Arch Dermatol Res. 2016;308:743-749. https://doi.org/10.1007/s00403-016-1697-9
Glaser DA, Hebert AA, Nast A, Werschler WP, Green L, Mamelok RD, et al. A 44-week open-label study evaluating safety and efficacy of topical glycopyrronium tosylate in patients with primary axillary hyperhidrosis. Am J Clin Dermatol. 2019;20:593-604. https://doi.org/10.1007/s40257-019-00446-6
Weinberg T, Solish N, Murray C. Botulinum neurotoxin treatment of palmar and plantar hyperhidrosis. Dermatol Clin. 2014;32:505-515. https://doi.org/10.1016/j.det.2014.06.012
Nawrocki S, Cha J. Botulinum toxin: pharmacology and injectable administration for the treatment of primary hyperhidrosis. J Am Acad Dermatol. 2020;82:969-979. https://doi.org/10.1016/j.jaad.2019.11.042
Rzany B, Bechara FG, Feise K, Heckmann M, Rapprich S, Wörle B. Update of the S1 guidelines on the definition and treatment of primary hyperhidrosis. J Dtsch Dermatol Ges. 2018;16:945-952. https://doi.org/10.1111/ddg.13579
Walling HW. Clinical differentiation of primary from secondary hyperhidrosis. J Am Acad Dermatol. 2011;64:690-695.
Kouris A, Armyra K, Christodoulou C, Karimali P, Karypidis D, Kontochristopoulos G. Quality of life in patients with focal hyperhidrosis before and after treatment with botulinum toxin a. ISRN Dermatol. 2014;2014:308650. https://doi.org/10.1155/2014/308650
Naumann MK, Hamm H, Lowe NJ. Effect of botulinum toxin type a on quality of life measures in patients with excessive axillary sweating: a randomized controlled trial. Br J Dermatol. 2002;147:1218-1226. https://doi.org/10.1046/j.1365-2133.2002.05059.x
Gregoriou S, Sidiropoulou P, Kontochristopoulos G, Rigopoulos D. Management strategies of palmar hyperhidrosis: challenges and solutions. Clin Cosmet Investig Dermatol. 2019;12:733-744. https://doi.org/10.2147/CCID.S210973
Singh S, Kaur S, Wilson P. Plantar hyperhidrosis: a review of current management. J Dermatolog Treat. 2016;27:556-561. https://doi.org/10.3109/09546634.2016.1163319
Campanati A, Gregoriou S, Milia-Argyti A, Kontochristopoulos G, Radi G, Diotallevi F, et al. The pharmacological treatment and management of hyperhidrosis. Expert Opin Pharmacother. 2022;23:1217-1231. https://doi.org/10.1080/14656566.2022.2083499
Lütgerath C, Weiß C, Faulhaber J, Karsai S. Comparison of a novel aluminum lactate-based with an aluminum chloride-based antiperspirant in excessive axillary and inguinal perspiration: first randomized controlled trial. J Dtsch Dermatol Ges. 2022;20:1589-1601. https://doi.org/10.1111/ddg.14898
Dolianitis C, Scarff CE, Kelly J, Sinclair R. Iontophoresis with glycopyrrolate for the treatment of palmoplantar hyperhidrosis. Australas J Dermatol. 2004;45:208-212. https://doi.org/10.1111/j.1440-0960.2004.00098.x
Rahim M, Ahmed N, Khan KN, Memon S, Naveed T, Shah SA, et al. Comparison of the efficacy of tap water iontophoresis versus aluminum chloride hexahydrate in the treatment of palmoplantar hyperhidrosis. Cureus. 2022;14:e32367. https://doi.org/10.7759/cureus.32367
Wong NS, Adlam TM, Potts GA, Farshchian M. Hyperhidrosis: a review of recent advances in treatment with topical anticholinergics. Dermatol Ther (Heidelb). 2022;12:2705-2714. https://doi.org/10.1007/s13555-022-00838-3
Kontochristopoulos G, Markantoni V, Agiasofitou E, Platsidaki E, Kouris A, Campanati A, et al. Treatment of primary axillary hyperhidrosis with a cream formulation of oxybutynin chloride 10%. J Eur Acad Dermatol Venereol. 2021;35:e524-e526. https://doi.org/10.1111/jdv.17297
Artzi O, Loizides C, Zur E, Sprecher E. Topical oxybutynin 10% gel for the treatment of primary focal hyperhidrosis: a randomized double-blind placebo-controlled split area study. Acta Derm Venereol. 2017;97:1120-1124. https://doi.org/10.2340/00015555-2731
Jeong SC, Kim JJ, Kim IS, Kim YH, Han JW, Moon SW. Effects of lower thoracic sympathicotomy on plantar hyperhidrosis. J Thorac Dis. 2021;13:664-670. https://doi.org/10.21037/jtd-20-2437
Bernhard MK, Krause M, Syrbe S. Sweaty feet in adolescents-early use of botulinum type a toxin in juvenile plantar hyperhidrosis. Pediatr Dermatol. 2018;35:784-786. https://doi.org/10.1111/pde.13628
Campanati A, Bernardini ML, Gesuita R, Offidani A. Plantar focal idiopathic hyperhidrosis and botulinum toxin: a pilot study. Eur J Dermatol. 2007;17:52-54. https://doi.org/10.1684/ejd.2007.0094
Vadoud-Seyedi J. Treatment of plantar hyperhidrosis with botulinum toxin type a. Int J Dermatol. 2004;43:969-971. https://doi.org/10.1111/j.1365-4632.2004.02304.x
Nasser S, Farschian M, Kimyai-Asadi A, Potts GA. Techniques to relieve pain associated with botulinum injections for palmar and plantar hyperhidrosis. Dermatol Surg. 2021;47:1566-1571. https://doi.org/10.1097/DSS.0000000000003182